Viking Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Viking Therapeutics, Inc. (VKTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $17.83 per share as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2026-07-29
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $17.83.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $17.14.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $14.18.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $14.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $17.83 10-Q · filed 2026-07-29 |
| 2026-03-31 | $17.14 10-Q · filed 2026-04-30 |
| 2025-12-31 | $14.18 10-Q · filed 2026-07-29 |
| 2025-09-30 | $14.00 10-Q · filed 2025-10-23 |
| 2025-06-30 | $13.92 10-Q · filed 2025-07-23 |
| 2025-03-31 | $13.79 10-Q · filed 2025-04-24 |
| 2024-12-31 | $11.10 10-K · filed 2026-02-11 |
| 2024-09-30 | $10.87 10-Q · filed 2024-10-23 |
| 2024-06-30 | $9.54 10-Q · filed 2024-07-24 |
| 2024-03-31 | $9.31 10-Q · filed 2024-04-25 |
| 2023-12-31 | $6.79 10-K · filed 2026-02-11 |
| 2023-09-30 | $6.78 10-Q · filed 2023-10-25 |
| 2023-06-30 | $6.66 10-Q · filed 2023-07-26 |
| 2023-03-31 | $5.82 10-Q · filed 2023-04-26 |
| 2022-12-31 | $5.45 10-K · filed 2026-02-11 |
| 2022-09-30 | $5.45 10-Q · filed 2022-10-26 |
| 2022-06-30 | $5.45 10-Q · filed 2022-07-27 |
| 2022-03-31 | $5.46 10-Q · filed 2022-04-27 |
| 2021-12-31 | $5.63 10-K · filed 2025-02-26 |
| 2021-09-30 | $5.62 10-Q · filed 2021-11-03 |
| 2021-06-30 | $5.62 10-Q · filed 2021-07-28 |
| 2021-03-31 | $5.64 10-Q · filed 2021-04-28 |
| 2020-12-31 | $5.57 10-K · filed 2024-02-07 |
| 2020-09-30 | $5.57 10-Q · filed 2020-10-28 |
| 2020-06-30 | $5.55 10-Q · filed 2020-07-29 |
| 2020-03-31 | $5.54 10-Q · filed 2020-04-30 |
| 2019-12-31 | $4.90 10-K · filed 2022-02-09 |
| 2019-09-30 | $4.86 10-Q · filed 2019-11-05 |
| 2019-06-30 | $4.76 10-Q · filed 2019-08-01 |
| 2019-03-31 | $4.77 10-Q · filed 2019-05-02 |
| 2018-12-31 | $3.72 10-K · filed 2021-02-17 |
| 2018-09-30 | $3.72 10-Q · filed 2018-11-07 |
| 2018-06-30 | $3.35 10-Q · filed 2018-08-09 |
| 2018-03-31 | $3.16 10-Q · filed 2018-05-09 |
| 2017-12-31 | $2.68 10-K · filed 2020-02-26 |
| 2017-09-30 | $2.67 10-Q · filed 2017-11-08 |
| 2017-06-30 | $2.67 10-Q · filed 2017-08-09 |
| 2017-03-31 | $2.75 10-Q · filed 2017-05-10 |
| 2016-12-31 | $4.28 10-K · filed 2019-03-13 |
| 2016-09-30 | $4.80 10-Q · filed 2016-11-10 |
| 2016-06-30 | $4.77 10-Q · filed 2016-08-11 |
| 2016-03-31 | $4.94 10-Q · filed 2016-05-10 |
| 2015-12-31 | $8.48 10-K · filed 2018-03-07 |
| 2015-09-30 | $8.41 10-Q · filed 2015-11-05 |
| 2015-06-30 | $8.87 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |